US Patent Issued to MEMORIAL SLOAN-KETTERING CANCER CENTER on Dec. 9 for "T cell receptors targeting PIK3CA mutations and uses thereof" (New York Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,492,237, issued on Dec. 9, was assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER (New York).

"T cell receptors targeting PIK3CA mutations and uses thereof" was invented by Christopher A. Klebanoff (New York) and Smita S. Chandran (Long Island City, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs h...